ReachMD
Be part of the knowledge.™Episodes 16-30 of 124
- 1
FDA Drug Information Updates
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
- 2
FDA Drug Information Updates
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
- 14
AudioAbstracts
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
- 2
FDA Drug Information Updates
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
- 3
Primary Care Today
Food-Proof: A USDA Expert's Tips for Avoiding Food Poisoning
Food-Proof: A USDA Expert's Tips for Avoiding Food Poisoning
- 1
FDA Drug Information Updates
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
- 1
Project Oncology®
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
- 1
Project Oncology®
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
- 1
Project Oncology®
FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
- 1
Project Oncology®
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
- 1
Project Oncology®
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
- 1
FDA Drug Information Updates
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
- 4
FDA Drug Information Updates
FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
- 4
FDA Drug Information Updates
Introducing FDA's Drug Information Soundcast in Clinical Oncology (DISCO)
Introducing FDA's Drug Information Soundcast in Clinical Oncology (DISCO)
- 0
The JAMA Report™
Study Examines Effectiveness of Steroid Medication for Sore Throat
Study Examines Effectiveness of Steroid Medication for Sore Throat
